No correlation between glycemic control and an increase in erythrocyte aldose reductase activity in type I and type II diabetic patients

Yoji Hamada, Katy Hammon, Philip Raskin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aldose reductase, the first enzyme of the polyol pathway, has been related to the pathogenesis of diabetic complications. The regulation of the enzyme in diabetes patients, however, has not yet been clarified. We recently reported that the activity of aldose reductase was increased in erythrocytes of insulin-dependent diabetes mellitus patients but short-term hyperglycemia did not affect the enzyme activity. It is still unclear, however, whether or not the increase in the enzyme activity is caused by long-term hyperglycemia and thus would be seen equally in both type I (insulin-dependent diabetes mellitus) and type 2 (non-insulin-dependent diabetes mellitus) individuals. To further clarify these issues we measured erythrocyte aldose reductase activity in 46 type I patients and 30 type II patients who had variable glucose control and in 16 nondiabetic subjects. We compared the enzyme activity with plasma glucose levels and hemoglobin A1c levels. The results show that erythrocyte aldose reductase activity is increased in both type I and type II patients as compared with nondiabetic subjects (7.1 ± 0.3 U/L and 6.8 ± 0.4 U/L erythrocytes versus 5.6 ± 0.2 U/L erythrocytes, p < 0.001 and p < 0.01, respectively), but there were no significant differences between the two groups of diabetic patients. The enzyme activity varied by approximately four times among the diabetic individuals but there was no correlation between the enzyme activity and plasma glucose or hemoglobin A1c levels. We conclude that the increased activity of erythrocyte aldose reductase seen in diabetes is not related to hyperglycemia.

Original languageEnglish (US)
Pages (from-to)111-115
Number of pages5
JournalJournal of Diabetes and its Complications
Volume6
Issue number2
DOIs
StatePublished - 1992

Fingerprint

Aldehyde Reductase
Erythrocytes
Enzymes
Hyperglycemia
Glucose
Hemoglobins
Diabetes Complications
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{6ed918fcbaea4c86bb2ab02d2021dd43,
title = "No correlation between glycemic control and an increase in erythrocyte aldose reductase activity in type I and type II diabetic patients",
abstract = "Aldose reductase, the first enzyme of the polyol pathway, has been related to the pathogenesis of diabetic complications. The regulation of the enzyme in diabetes patients, however, has not yet been clarified. We recently reported that the activity of aldose reductase was increased in erythrocytes of insulin-dependent diabetes mellitus patients but short-term hyperglycemia did not affect the enzyme activity. It is still unclear, however, whether or not the increase in the enzyme activity is caused by long-term hyperglycemia and thus would be seen equally in both type I (insulin-dependent diabetes mellitus) and type 2 (non-insulin-dependent diabetes mellitus) individuals. To further clarify these issues we measured erythrocyte aldose reductase activity in 46 type I patients and 30 type II patients who had variable glucose control and in 16 nondiabetic subjects. We compared the enzyme activity with plasma glucose levels and hemoglobin A1c levels. The results show that erythrocyte aldose reductase activity is increased in both type I and type II patients as compared with nondiabetic subjects (7.1 ± 0.3 U/L and 6.8 ± 0.4 U/L erythrocytes versus 5.6 ± 0.2 U/L erythrocytes, p < 0.001 and p < 0.01, respectively), but there were no significant differences between the two groups of diabetic patients. The enzyme activity varied by approximately four times among the diabetic individuals but there was no correlation between the enzyme activity and plasma glucose or hemoglobin A1c levels. We conclude that the increased activity of erythrocyte aldose reductase seen in diabetes is not related to hyperglycemia.",
author = "Yoji Hamada and Katy Hammon and Philip Raskin",
year = "1992",
doi = "10.1016/1056-8727(92)90021-C",
language = "English (US)",
volume = "6",
pages = "111--115",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - No correlation between glycemic control and an increase in erythrocyte aldose reductase activity in type I and type II diabetic patients

AU - Hamada, Yoji

AU - Hammon, Katy

AU - Raskin, Philip

PY - 1992

Y1 - 1992

N2 - Aldose reductase, the first enzyme of the polyol pathway, has been related to the pathogenesis of diabetic complications. The regulation of the enzyme in diabetes patients, however, has not yet been clarified. We recently reported that the activity of aldose reductase was increased in erythrocytes of insulin-dependent diabetes mellitus patients but short-term hyperglycemia did not affect the enzyme activity. It is still unclear, however, whether or not the increase in the enzyme activity is caused by long-term hyperglycemia and thus would be seen equally in both type I (insulin-dependent diabetes mellitus) and type 2 (non-insulin-dependent diabetes mellitus) individuals. To further clarify these issues we measured erythrocyte aldose reductase activity in 46 type I patients and 30 type II patients who had variable glucose control and in 16 nondiabetic subjects. We compared the enzyme activity with plasma glucose levels and hemoglobin A1c levels. The results show that erythrocyte aldose reductase activity is increased in both type I and type II patients as compared with nondiabetic subjects (7.1 ± 0.3 U/L and 6.8 ± 0.4 U/L erythrocytes versus 5.6 ± 0.2 U/L erythrocytes, p < 0.001 and p < 0.01, respectively), but there were no significant differences between the two groups of diabetic patients. The enzyme activity varied by approximately four times among the diabetic individuals but there was no correlation between the enzyme activity and plasma glucose or hemoglobin A1c levels. We conclude that the increased activity of erythrocyte aldose reductase seen in diabetes is not related to hyperglycemia.

AB - Aldose reductase, the first enzyme of the polyol pathway, has been related to the pathogenesis of diabetic complications. The regulation of the enzyme in diabetes patients, however, has not yet been clarified. We recently reported that the activity of aldose reductase was increased in erythrocytes of insulin-dependent diabetes mellitus patients but short-term hyperglycemia did not affect the enzyme activity. It is still unclear, however, whether or not the increase in the enzyme activity is caused by long-term hyperglycemia and thus would be seen equally in both type I (insulin-dependent diabetes mellitus) and type 2 (non-insulin-dependent diabetes mellitus) individuals. To further clarify these issues we measured erythrocyte aldose reductase activity in 46 type I patients and 30 type II patients who had variable glucose control and in 16 nondiabetic subjects. We compared the enzyme activity with plasma glucose levels and hemoglobin A1c levels. The results show that erythrocyte aldose reductase activity is increased in both type I and type II patients as compared with nondiabetic subjects (7.1 ± 0.3 U/L and 6.8 ± 0.4 U/L erythrocytes versus 5.6 ± 0.2 U/L erythrocytes, p < 0.001 and p < 0.01, respectively), but there were no significant differences between the two groups of diabetic patients. The enzyme activity varied by approximately four times among the diabetic individuals but there was no correlation between the enzyme activity and plasma glucose or hemoglobin A1c levels. We conclude that the increased activity of erythrocyte aldose reductase seen in diabetes is not related to hyperglycemia.

UR - http://www.scopus.com/inward/record.url?scp=0026969226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026969226&partnerID=8YFLogxK

U2 - 10.1016/1056-8727(92)90021-C

DO - 10.1016/1056-8727(92)90021-C

M3 - Article

VL - 6

SP - 111

EP - 115

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 2

ER -